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Familial Alzheimer’s disease-causing 
mutations in the presenilins increase 
production of longer, pathogenic amyloid β  
peptides (Aβ42/43) by altering γ-secretase 
activity.  The mechanism underlying this 
effect remains unknown, although it has been 
proposed that heteromeric macromolecular 
complexes containing presenilins mediate 
γ-secretase cleavage of the amyloid β  precursor 
protein.  Using a random mutagenesis screen 
of presenilin 1 (PS1) for 
PS1-endoproteolysis-impairing mutations, we 
identified five unique mutants including R278I- 
and L435H-PS1, which exclusively generated a 
high level of Aβ43 but that did not support 
physiological PS1 endoproteolysis or Aβ40 
generation.  These mutants did not 
measurably alter the molecular size or 
subcellular localization of PS1 complexes.  
Pharmacological studies indicated that the 
upregulation of activity for Aβ43 generation by 
these mutations was not further enhanced by 
the difluoroketone inhibitor DFK167 and was 
refractory to inhibition by sulindac sulfide.  
These results suggest that PS1 mutations can 
lead to a wide spectrum of changes in the 
activity and specificity of γ-secretase and that 
the effects of PS1 mutations and γ-secretase 
inhibitors on the specificity are mediated 
through a common mechanism.  
 
     The amyloid β-precursor protein (APP)1, 
Notch, ErbB-4, and several other unrelated type 1 
transmembrane (TM) proteins undergo γ-secretase 
cleavage within their TM domains (1, 2).  The 
consequential proteolytic release of intracellular 
domains of these substrates has been revealed to 
be involved in signaling from the membrane to the 
nucleus (3).  In the case of APP, γ-secretase 
mediates γ- and ε-cleavage to generate a 
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heterogeneous series of N- and C-terminal 
products, named amyloid β peptides (Aβ) and 
APP intracellular domain (AICD), respectively.  
Aβ peptides have C-termini that end at residues 
38, 40, 42, or 43, while AICD fragments begin at 
residues 48 to 52 of the Aβ peptide domain (4, 5).  
The process regulating these heterogeneous 
intramembranous cleavages is poorly understood 
but is a central issue in Alzheimer’s disease (AD) 
research for three reasons.  First, the longer Aβ 
species ending at residue 42 or 43 (Aβ42/43) are 
thought to play a critical role in the pathogenesis 
of AD, although they are minor products of 
normal γ-secretase activity (6).  Second, clinical 
mutations in the presenilins (PSs), which are 
responsible to the majority of familial AD (FAD) 
pedigrees, cause increased ratio of Aβ42/43 
isoforms to total Aβ (7).  Third, medication that 
modulates the Aβ42/43 production by altering 
γ-secretase activity could provide an effective 
therapy for AD.  
     Presenilin 1 and 2 (PS1 and PS2) are 
multi-pass TM proteins and undergo 
endoproteolysis within their large cytoplasmic 
loop domains by an unknown protease named 
presenilinase (PSase) (8, 9).  This 
endoproteolysis yields N- and C-terminal 
fragments (NTF and CTF, respectively) that are 
stabilized and assembled into functional 
macromolecular complexes together with at least 
three other membrane proteins, nicastrin (Nct), 
APH-1 and PEN-2 (10, 11).  The abundance and 
stoichiometry of PS complexes are tightly 
regulated, and exogenously over-expressed PSs 
can replace endogenous PSs (8).  Recent studies 
have suggested that these multiprotein complexes 
mediate γ-secretase cleavage and probably PS 
endoproteolysis and that PSs may be the catalytic 
components of the complexes (2, 12-15).  
Furthermore, it has been presumed that 
FAD-associated mutations of the PSs significantly 
alter γ-secretase activity and enhance production 
of Aβ42/43 through a gain-of-function effect.  
However, it is still unclear how more than a 
hundred of FAD-linked missense mutations 
scattered throughout the sequence of PSs can 
selectively upregulate the enzymatic production of 
Aβ42/43.  
     While trying to address this conundrum, we 
realized that the FAD-linked mutations and the 
few site-directed mutagenesis studies described to 
date (12, 16-19) did not provide an unbiased view 
of the effects of PS mutations on γ-secretase 
activity.  Thus, the clinical mutations were 
ascertained by linkage to FAD, whereas the 
site-directed mutations in conserved residues were 
created to test specific hypotheses.  We therefore 
undertook a screen of randomly mutagenized PS1 
to identify single-residue missense mutations that 
affected the physiological endoproteolysis of PS1 
and/or selectively changed Aβ isoform production.  
We report here the discovery and characterization 
of novel mutant PS1 that exclusively generate 
longer Aβ species, but which do not support the 
activities for Aβ40 generation or PS1 
endoproteolysis.  
 
EXPERIMENTAL PROCEDURES 
 
     Antibodies and reagents - The rabbit 
polyclonal antibody against the N-terminus of PS1 
was previously described (10).  Monoclonal 
antibodies against PS1 CTF and APP NTF 
(22C11) and a polyclonal antibody against APP 
CTF were purchased from Chemicon (Temecula, 
CA).  Polyclonal anti-nicastrin (N1660) and 
monoclonal anti-Flag tag (M2) antibodies were 
from Sigma (St. Louis, MO).  Monoclonal 
antibodies against p115 and Myc tag (9E10) were 
obtained from BD Biosciences (Franklin Lakes, 
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NJ) and Santa Cruz Biotechnology (Santa Cruz, 
CA), respectively.  Cycloheximide, DFK167 and 
sulindac sulfide were purchased from Sigma, 
Enzyme Systems Products (Livermore, CA) and 
Wako (Osaka, Japan), respectively.  
     Cell culture and cDNA transfection - 
Human embryonic kidney 293 (HEK293) cells 
and mouse embryonic fibroblasts derived from 
PS1-, PS2-double knock-out mouse (PS-null 
MEFs) (20) were cultured in Dulbecco’s modified 
Eagle medium supplemented with 10% fetal 
bovine serum and 1% streptomycin/penicillin.  
cDNA transfection was carried out using 
LipofectAMINE Plus reagent (Invitrogen, 
Carlsbad, CA).  
     Generation and screening of a randomly 
mutagenized PS1 cDNA library - Random 
mutagenesis of PS1 cDNA was performed by 
error-prone PCR with the forward primer 
5’-TTTTGAATTCTCCTTAGACAGCTTGGCC
TGGAG-3’, corresponding to the 5’-untranslated 
region of human PS1 cDNA and containing an 
EcoRI restriction site; and with the reverse primer 
5’-TTTTCTCGAGACCTTTGTCCTCCCCAGA
TTTGG-3’, corresponding to the 3’-untranslated 
region and containing an XhoI site.  PCR 
conditions were determined for low frequency 
mutagenesis according to the manufacturer’s 
instructions (Stratagene, La Jolla, CA).  By 
sequencing 10 PCR products, we confirmed that 
the number of nucleotide substitutions per PS1 
cDNA ranged from zero to seven.  Mutagenized 
PS1 cDNA fragments obtained from four different 
PCR reactions were cloned into the EcoRI/XhoI 
sites of pCMV-script (Stratagene).  Site-directed 
mutagenesis for subsequent confirmatory 
experiments was carried out using the 
QuikChange mutagenesis kit (Stratagene) and 
appropriate synthesized oligonucleotide primers.  
For screening for endoproteolysis-impaired 
mutants, PS-null MEFs were transfected with 
each mutagenized PS1 cDNA.   At 48 h after 
transfection, cells were harvested and 
homogenized in a Teflon-glass homogenizer.  
Crude membrane fractions were isolated from the 
postnuclear supernatants by centrifugation at 
12,000g for 30 min and then subjected to Western 
analysis with an antibody against PS1. 
     Retrovirus-mediated gene expression - The 
retroviral infection of PS-null MEFs was carried 
out as described (21).  Briefly, PLATE-E 
packaging cells were transfected with a retroviral 
vector, pMXs, carrying the cDNA encoding PS1 
or human APP using FuGene-6 (Roche 
Diagnostics).  Culture media collected two days 
after transfection were used for viral stocks.  For 
infection, MEFs were incubated with virus stock 
containing 10 µg/ml Polybrene (Sigma) for 6 h.  
A day after infection, the medium was replaced 
with fresh Dulbecco’s modified Eagle medium 
supplemented with 10% fetal bovine serum and 
1% streptomycin/penicillin, and the MEFs were 
cultured for another 48 h for the preparation of 
conditioned media to be used in Aβ measurements.  
The infection efficiency was more than 95% in 
this study, estimated by a control experiment 
using pMXs-GFP that carried cDNA for jellyfish 
green fluorescent protein.  
     Immunoprecipitation and Western analysis 
-  Cells or membrane fractions were lysed in 
lysis buffer (25 mM HEPES at pH 7.5, 150 mM 
NaCl, 2 mM EDTA and 10% glycerol) containing 
1% NP40 and protease inhibitor cocktail (Roche 
Diagnostics).  Western blotting was performed 
as previously described (10).  For 
immunoprecipitation, cells were lysed in lysis 
buffer containing 1% 
3-[(3-cholamidopropyl)dimethylammonio]-2-hydr
oxy-1-propanesulfonic acid (CHAPSO).  After 
preclearing with protein A-Sepharose CL-4B 
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(Amersham Biosciences, Uppsla, Sweden), cell 
lysates were incubated with antibody for 2 h, 
followed by overnight incubation with protein 
A-Sepharose at 4ºC.  The immunoprecipitates 
were washed three times with 1% CHAPSO 
buffer and analyzed by Western blotting.  
     Glycerol velocity gradient centrifugation - 
Glycerol velocity gradient centrifugation was 
carried out as previously described (22).  
HEK293 cells transfected with PS1 cDNA were 
disrupted with a Polytron homogenizer 
(Kinematica, Littau-Luzern, Switzerland), and 
nuclei and large cell debris were sedimented by 
centrifugation at 1,500 g for 10 min.  The 
postnuclear supernatants were centrifuged at 
100,000 g for 1 h in a Beckman ultracentrifuge to 
prepare crude membrane fractions.  After 
solubilization in lysis buffer containing 1% 
CHAPSO, membrane fractions were applied onto 
the top of 15 to 30% (w/v) linear glycerol 
gradients.  The gradients were centrifuged at 
36,000 g for 18 h and split into 12 fractions from 
the bottom.  The fractionated proteins were 
analyzed by Western blotting.  Ferritin (440 
kDa), β amylase (200 kDa), lactate dehydrogenase 
(140 kDa) and bovine serum albumin (67 kDa) are 
used as molecular weight markers.  
     Evaluation of PS-dependent cleavages of 
APP and Notch - For analysis of AICD generation, 
crude membrane fractions were obtained from 
HEK293 cells expressing various PS1 mutants 
and were solubilized in lysis buffer containing 
0.5% CHAPSO and 5 mM 1,10-phenanthroline 
(Sigma).  The lysates were incubated for 1 h at 
37ºC and analyzed by Western blotting.  For 
assessment of Notch intracellular domain (NICD) 
generation, HEK293 cells expressing the PS1 
mutant were transiently transfected with NotchΔE 
tagged with Myc epitopes (23).  After starvation 
in Met-free medium, cells were metabolically 
labeled for 20 min with 500 µCu/ml 35S-Met (ICN 
Biomedicals) and then incubated for 1 h in 
complete Dulbecco’s modified Eagle medium 
supplemented with 10% fetal bovine serum.  Cell 
lysates were immunoprecipitated with anti-Myc 
antibody and separated by polyacrylamide gel 
electrophoresis.  Secreted Aβ levels were 
measured by enzyme-linked immunosorbent 
assays (ELISAs) specific for Aβ40 or Aβ42/43 as 
described (24).  
     Immunoprecipitation/mass spectrometry 
analysis - Immunoprecipitation/mass 
spectrometry (IP/MS) analysis of Aβ peptides was 
performed as previously described (4).  Secreted 
Aβ peptides in conditioned media were 
immunoprecipitated with the monoclonal antibody 
4G8 (Senetek, Napa, CA) using Protein A/G-Plus 
agarose beads (Santa Cruz Biotechnology).  Aβ 
peptides were analyzed by matrix-assisted laser 
desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF-MS) using a 
Voyager-DE STR mass spectrometer (Applied 
Biosystems, Foster City, CA).  Each mass 
spectrum was averaged from 1,000 measurements 
and calibrated with bovine insulin as an internal 
calibrant.  
     Immunocytochemistry - Cells were fixed 
with 4% paraformaldehyde for 15 min and were 
then permeabilized with 0.1% Triton X-100 for 5 
min.  Nonspecific antibody binding was blocked 
by incubating cells with 5% normal goat serum 
for 1 h.  For double staining, fixed cells were 
incubated overnight at 4°C with a mixture of 
primary antibodies, followed by reaction for 2 h 
with Alexa Fluor 594-conjugated anti-rabbit and 
Alexa Fluor 488-conjugated anti-mouse secondary 
antibodies (Molecular Probes).  The slides were 
analyzed with an LSM510 confocal 
laser-scanning microscope (Carl Zeiss, 
Oberkochen, Germany).  
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     Subcellular fractionation with 
discontinuous sucrose gradients - Subcellular 
fractionation was performed according to a 
previously described method (22).  HEK293 
cells transfected with PS1 cDNA were 
homogenized with a Polytron homogenizer in a 
buffer (5 mM HEPES at pH 7.2, 1 mM EDTA and 
protease inhibitor cocktail).  Postnuclear 
supernatant was obtained by centrifugation at 
1,000 g for 10 min and loaded on the top of a 
discontinuous sucrose gradient (1 ml/2.0 M, 3.4 
ml/1.3 M, 3.4 ml/1.0 M and 2.7 ml/0.6 M) made 
up in the same buffer.  The gradient was 
centrifuged for 2 h at 280,000 g in a Beckman 
ultracentrifuge and 24 fractions were collected 
from the bottom of the tube with a peristaltic 
pump.  Fractions were trichloroacetic 
acid-precipitated, and proteins were analyzed by 
Western blotting. 
 
RESULTS 
 
     Random mutagenesis screen identified 
novel endoproteolysis-impaired PS1 mutants - We 
generated and screened a randomly mutagenized 
PS1 cDNA library to identify mutants that were 
defective in PS1 endoproteolysis.  We isolated 
370 clones that were then transiently transfected 
into PS-null MEFs.  On Western analysis, 33 of 
the PS1 mutants displayed impaired PS1 
endoproteolysis.  DNA sequencing revealed that 
7 of these mutants had nonsense mutations.  The 
remaining 26 mutants harbored missense 
mutations that were located throughout the 
molecule (data not shown).  Six of these 26 
mutants contained single amino acid substitutions, 
which were S141R, T245I, R278I, P433L, A434T 
and L435H (Fig. 1A and B).  The S141 and T245 
residues are located within the second and sixth 
TM domains, respectively, and are not conserved 
in homologues of Caenorhabditis elegans.  R278 
is a conserved residue at the N-terminus of the 
cytoplasmic loop between TM6 and TM7; and 
P433, A434 and L435 are located in the highly 
conserved PAL motif in the cytoplasmic 
C-terminal tail (17).  
     Mutant PS1 proteins form stable, high 
molecular weight complexes - To assess the 
functional properties of these mutant PS1, each 
was stably transfected into HEK293 cells that also 
expressed a construct equivalent to the C-terminal 
β-secretase-processed APP fragment (C99), which 
is the immediate substrate for γ-secretase and 
yields Aβ.  Because functional endoproteolytic 
derivatives of wild-type (WT) PS1 assemble into 
a stable, high molecular weight (MW) complex 
(22), we initially investigated: 1) the incorporation 
of each mutant into macromolecular complexes; 
2) the ability of each mutant to replace 
endogenous PS1; and 3) the metabolic half-life of 
each mutant protein.  Glycerol velocity gradient 
analyses revealed that the uncleaved mutant 
holoproteins were assembled into high MW 
complexes that were of similar size as the 
endogenous complexes (~200 to 400 kDa), 
although the complexes containing S141R and 
T245I mutants were also distributed broadly into 
the lower MW ranges (Fig. 1C).  The mutant 
holoproteins also displaced the proteolytic 
fragments of endogenous presenilins (Fig. 1C).  
Reciprocal co-immunoprecipitation assays 
confirmed that, similar to WT-PS1, all six PS1 
mutants bound to the other γ-secretase 
components (Nct, APH-1 and PEN-2) (data not 
shown).  As shown in Fig. 1D, the half-lives of 
the mutant holoproteins in the presence of 
cycloheximide were comparable to those of WT 
proteolytic fragments (t1/2 > 24 h) and were much 
longer than the half-life of WT holoprotein (t1/2 < 
1 h).  The S141R- and T245I-PS1 holoproteins 
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were less well stabilized (t1/2 = ~8 and ~4 h, 
respectively).  Taken together, all six mutations 
specifically prevented PS1 endoproteolysis but 
did not significantly impede the assembly and 
stabilization of mutant PS1 complexes.  
     Proteolytic activities of mutant PS1 - To 
investigate the ability of these mutants to support 
γ- and ε-cleavage of APP, we measured the 
production of AICD and Aβ from HEK293 cell 
lines expressing mutant PS1 and APP-C99.  In 
comparison to cells expressing WT-PS1, the 
generation of AICD was clearly suppressed in all 
six mutant cell lines (Fig. 2A).  Similarly, S3 
cleavage of Notch, which corresponds to 
ε-cleavage of APP, was clearly attenuated (Fig. 
2B).  An ELISA specific for Aβ40 or Aβ42/43 
revealed that the levels of Aβ40 secreted from 
mutant PS1-expressing cells were either 
comparable to or were lower than the level of 
Aβ40 secreted from WT-PS1 cells (Fig. 2C).  In 
contrast, the level of secreted Aβ42/43 was 
significantly elevated in five of six mutant cell 
lines.  Finally, P433L-PS1 cells secreted less 
Aβ40 and Aβ42/43 than WT-PS1 cells.  These 
mutants exhibited dominant phenotypes for the 
secretion of Aβ40 and Aβ42/43 presumably through 
the replacement of endogenous PSs.   
     To assess the γ-secretase activity of these 
mutants in the absence of endogenous PSs, we 
transfected each of these PS1 mutants together 
with human APP into PS-null MEFs using 
retroviral vectors and then measured Aβ levels in 
the conditioned media from these cells (Fig. 3A).  
Transfection of WT-PS1 successfully restored Aβ 
secretion, whereas, compared to transfection with 
WT-PS1, transfection of FAD-causing mutants 
(I143F- and L392V-PS1) led to Aβ secretion with 
an increased ratio of Aβ42/43 to total Aβ.  The 
P433L mutant did not restore Aβ secretion, 
supporting the idea that P433L is a 
loss-of-function mutation (17, 25).  In contrast, 
the five other mutants secreted significant 
amounts of Aβ42/43, while secreting only minimal 
or background levels of Aβ40.  Because R278I 
and L435H mutants generated particularly high 
levels of Aβ42/43, we focused on these mutants in 
the following experiments.  
     To reveal the profile of Aβ species secreted 
by MEFs expressing the R278I- or L435H-PS1, 
we performed IP/MS as previously described (4).  
The spectrum of MALDI-TOF-MS indicated that 
the Aβ species secreted by these MEFs always 
ended at residue Thr43 (i.e., Aβ11-43 and Aβ1-43; 
Fig. 3B).  These mutants are quite unique in 
exclusively generating Aβ43 and are therefore 
designated PS1LA (PS1 yielding longer Aβ).  
     The R278I and L435H mutations are 
located in the NTF and CTF of PS1, respectively 
(Fig. 1B).  To determine whether these mutations 
might have cooperative or additive effects, we 
generated a PS1 cDNA harboring both mutations 
in cis.  When expressed in PS-null MEFs, this 
double mutant formed a holoprotein that was 
incorporated into stable high MW complexes, but 
rescued neither Aβ40 nor Aβ42/43 secretion (data 
not shown).  This suggests that double PS1LA 
mutation causes a loss of γ-secretase activity and 
that PS1LA are incomplete loss-of-function 
mutations.  
     PS1 endoproteolysis is thought to occur 
during PS1 complex maturation and prior to the 
activation of γ-secretase (13).  To exclude the 
possibility that the inefficient endoproteolysis of 
the mutant holoproteins had affected the cleavage 
specificity of γ−secretase, we simulated 
endoproteolysis of the mutant proteins by 
co-infecting PS-null MEFs with two cDNAs: one 
encoding the PS1-NTF (residues 1 to 291), the 
other encoding the PS1-CTF (residues 292 to 467).  
In both cases, the R278I and L435H mutations 
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were contained in the appropriate hemi-constructs.  
The ratios of Aβ42/43 to total Aβ produced in these 
experiments were comparable to those produced 
in PS-null MEFs infected with the corresponding 
full-length cDNA (Fig. 3C).  These results 
confirm that γ-secretase activity was modified by 
the specific amino acid substitution rather than 
due to the lack of endoproteolysis of the mutant 
holoprotein.  
     R278I mutation does not alter subcellular 
localization of PS1 protein - Previous studies have 
suggested that Aβ40 and Aβ42/43 arise from 
γ-secretase cleavage at distinct subcellular 
locations (26-28).  However, three observations 
argue that simple mistrafficking of the PS1LA 
mutants is not the reason for Aβ42/43 production.  
First, there were no significant differences in the 
subcellular distribution of WT-PS1 CTF and 
R278I-PS1 holoprotein in immunocytochemical 
experiments or upon subcellular fractionation with 
sucrose gradients (Fig. 4A and B).  Both PS1 
species appeared to be similarly transported from 
the ER to the Golgi apparatus.  Second, the 
pattern of Nct glycosylation in 
R278I-PS1-expressing cells was indistinguishable 
from that in WT-PS1-expressing cells (Fig. 4C).  
Finally, the selective over-production of Aβ42/43 
by R278I- or L435H-PS1 cells was still evident 
even when Aβ peptides were generated in a 
solubilized membrane fraction prepared from 
these cells (Fig. 4D).  
     Different amino acid substitutions at the 
same residue can result in distinct modifications 
of γ-secretase activity - The PS1 R278I mutation 
conferred exclusive generation of Aβ43, whereas 
the P433L mutation resulted in loss-of-function.  
To address whether these substitutions have a 
specific role in PS1 endoproteolysis and 
γ-secretase activities, we generated and tested 
additional mutations at these residues.  We 
introduced five other mutations into the R278 
codon, including FAD-linked R278K and R278T 
as well as substitutions to S, E, and P, which have 
polar, negatively charged, and imino group side 
chains, respectively.  Unlike the R278I mutation, 
all of these substitutions increased the levels of 
secreted Aβ42/43, but did not affect either PS1 
endoproteolysis or Aβ40 secretion (Fig. 5A).  
     Next we generated seven mutations at the 
P433 residue and tested γ-secretase activity (Fig. 
5B).  Similar to P433L-PS1, mutant PS1 bearing 
substitution of P433 with I, E, K, or Q was not 
cleaved and could not restore Aβ secretion when 
expressed in PS-null MEFs.  In contrast, but 
similar to PS1LA mutations, the P433S and P433G 
mutations caused impaired self-endoproteolysis, 
reduced Aβ40 secretion and enhanced Aβ42/43 
generation.  Finally, like FAD-linked mutants, 
P433A-PS1 was cleaved normally and exhibited a 
high ratio of Aβ42/43 to total Aβ.  A434C and 
L435F, FAD-linked mutations at the neighboring 
residues of P433, caused enhanced secretion of 
Aβ42/43 (data not shown), and, very recently, 
A434D and L435R were reported to be 
loss-of-function mutations (25).  Altogether, 
these results indicate that different amino acid 
substitutions at the same residue can result in 
distinct modifications of γ-secretase activity.   
     Pharmacological assessment of PS1LA 
mutant-associated protease activities - In addition 
to mutations of PSs and APP, γ-secretase 
inhibitors are also known to modulate the ratio of 
Aβ42/43 to total Aβ (29-31).  Previous reports 
have shown that FAD-linked mutations attenuate 
the effect of γ-secretase inhibitors (32-34); 
however, these data were obtained from cells 
expressing both WT and mutant PS1.  We 
therefore re-evaluated the effects of γ-secretase 
inhibitors using MEFs expressing a single 
genotype of PS1.  The results in Fig. 6A confirm 
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previous reports (30, 35, 36) and show that, in 
MEFs expressing WT-PS1, the peptidomimetic 
difluoroketone inhibitor DFK167 selectively 
enhanced the γ-secretase activity of Aβ42/43 
generation (γ-42/43) at sub-inhibitory doses, but 
inhibited the γ-secretase activity of Aβ40 
generation (γ-40) in a dose-dependent manner.  
However, this enhancement of Aβ42/43 secretion 
was abolished in MEFs expressing R278I-PSI, 
and in agreement with the prior report (33), was 
relatively attenuated in FAD-linked I143F-PS1 
MEFs as compared with WT-PS1 MEFs 
(maximum-fold increases: 0.96 ± 0.01, 1.76 ± 
0.08, and 2.06 ± 0.14, respectively; means ± s.d. 
[n = 3]; p < 0.001 by Bonferroni post-hoc test).  
     Sulindac sulfide, a non-steroidal 
anti-inflammatory drug (NSAID), preferentially 
inhibits γ-42/43 activity (31, 34, 37, 38).  Fig. 6B 
shows that this inhibitory effect was obviously 
reduced in R278I-PS1MEFs and was 
intermediately decreased in I143F-PS1 MEFs as 
compared to WT-PS1 MEFs (fold decreases at 60 
µM: 0.96 ± 0.08, 0.49 ± 0.01, and 0.12 ± 0.08, 
respectively; means ± s.d. [n = 3]; p < 0.001 by 
Bonferroni post-hoc test).  Paradoxically, Aβ40 
secretion was enhanced by sulindac sulfide in 
R278I-PS1 MEFs (maximal fold increase: 3.30 ± 
0.28; mean ± s.d. [n = 3]).  The inhibition profile 
of DFK167 or sulindac sulfide in L435H-PS1 
MEFs was similar to that of R278I-PS1 (data not 
shown).  Based on these results, it appears that 
DFK167 and sulindac sulfide have opposite 
effects; specifically, DFK167 preferentially 
inhibited γ-40 of PS1LA cells and enhanced 
γ-42/43 in WT-PS1 cells, whereas sulindac sulfide 
paradoxically enhanced γ-40 of PS1LA cells and 
inhibited γ-42/43 in WT-PS1 cells.  These results 
suggest an incomplete reciprocal relationship 
between γ-40 and γ-42/43 activities.  
Additionally, it appears that PS1LA mutations 
cause similar but exaggerated modification on Aβ 
secretion as compared to FAD-linked mutations.   
     It has been reported that DFK167 inhibits 
PS1 endoproteolysis in an in vitro assay system 
(39).  However, when DFK167 was applied to 
cells expressing WT-PS1 or FAD-linked 
I143F-PS1, the endoproteolysis was unaffected 
(Fig. 6C).  Unexpectedly, when DFK167 was 
applied to cells expressing the R278I- or 
L435H-PS1 mutant, the endoproteolysis was 
activated in a dose-dependent manner (Fig. 6C).  
This paradoxical activation was highly specific to 
these mutants; DFK167 had no effect on the failed 
endoproteolysis of loss-of-function mutants such 
as D385A- or P433L-PS1.  
 
DISCUSSION 
 
     In this study, we found six missense 
mutations of PS1 by a random mutagenesis screen 
for PS1-endoproteolysis-impaired mutants.  
These mutations fell into two categories: PS1LA 
and the loss-of-function mutant P433L-PS1.  
These mutations did not significantly affect the 
complex assembly and stabilization of uncleaved 
mutant holoproteins.  PSase cleavage is tightly 
related to γ-secretase activity, although PS 
endoproteolysis is not absolutely required for the 
activation of γ-secretase (12, 40).  Both activities 
required two intramembranous aspartyl residues at 
the putative catalytic sites of PS (D257 and D385 
of PS1) (12), and certain γ-secretase inhibitors 
blocked PSase cleavage as well (41, 42).  
However, the profiles of their response to 
inhibitors were different from one another (39, 41).  
Additionally, a recent report proved that D257A- 
or D385A-PS1 holoprotein was cleaved, although 
with low efficiency, without any concomitant 
γ-secretase activity, when stably expressed in 
PS-null cells (43).  Nevertheless, in most cases, 
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except mutants harboring mutations at the 
cleavage site (e.g. M292D-PS1) (40, 44, 45), the 
previously reported cleavage-defective mutations 
simultaneously conferred definitive modification 
of γ-secretase activity and/or specificity (12, 16, 
17, 25, 46).  This is the case for PS1LA mutants, 
which are distinctive in mediating exclusively 
γ-43 cleavage of APP but not self-endoproteolysis, 
γ-40 and ε-cleavage.  Aβ43 is a minor Aβ product 
of normal γ-secretase activity but the longest 
identified so far, and its secretion, like Aβ42, is 
associated with pathogenic PS1 mutations (33) or 
DFK167 treatment (36).  
     Together with previous work, our results 
suggest that PS mutations allow the existence of at 
least four activity states of γ-secretase.  The 
lowest activity state is exemplified by 
loss-of-function mutations such as D257A, 
D385A, G384K and P433L (12, 16, 17).  The 
next lowest active state is typified by the PS1LA 
mutants, in which there is residual 
self-endoproteolysis, γ-40 and ε-cleavage, but 
relatively high γ-42/43 activity.  A further stage 
of activation, generally supporting normal 
self-endoproteolysis and γ-40 activity but reduced 
ε-cleavage and enhanced γ-42/43 activity, is 
represented by many FAD mutants (5, 18, 33).  
Finally, WT-PS1 represents the fully functional 
state, wherein PS1 supports self-endoproteolysis, 
ε-cleavage, predominant γ-40 activity, and minor 
γ-42/43 activity.  A few FAD mutants have been 
reported to show reduced self-endoproteolysis and 
decreased Aβ40 secretion as well as enhanced 
Aβ42/43 secretion (41, 47), which somewhat 
resemble the activity state of PS1LA mutants.  
Meanwhile, during preparation of this manuscript, 
R278I PS1LA mutation has been reported to 
co-segregate with family members affected with 
early-onset, atypical FAD (48).  These suggest 
that PS1LA mutants have similar but exaggerated 
effects on γ-secretase activity as compared to 
typical FAD mutants.  PS1 mutations appear to 
result in a wide spectrum of γ-secretase activity 
that is associated with a shift in cleavage 
specificity.  
     Two of the five PS1LA mutations and the 
P433L loss-of-function mutation were clustered at 
the highly conserved PAL sequence in the 
C-terminal tail.  The R278 residue is remote on 
the sequence from, but can be located close to the 
PAL motif near the cytoplasmic face of the 
membrane on the tertiary conformation based on 
the eight-TM model of PS1 proteins (Fig. 1B; 49).  
These residues may compose of a conformational 
domain that is important not only for the activity 
but also for the cleavage specificity of γ-secretase.  
However, the two other mutations S141R and 
T245I, which had a weaker effect, were not 
located in close proximity, suggesting that 
multiple domains can affect the γ-secretase 
activity and specificity.  On the other hand, our 
results indicate that different amino acid 
substitutions at the same residue of PS1 can cause 
distinct modifications of γ-secretase activity.  
These results confirm and extend previous studies 
showing that several mutations at residue 166 or 
384 differentially affect secreted Aβ level and the 
Aβ42/total Aβ ratio (16, 18).  These observations 
suggest that the effect of PS mutations on the 
γ-secretase activity and specificity is not mediated 
by simple loss of function of a restricted domain 
or motif.   
     Recent studies suggest that γ-secretase 
complexes contain dimerized PS1 or PS2 and that 
two interfaces with diaspartyl combination in the 
TM region form catalytic sites (47).  
Non-competitive inhibition by the transition state 
analogue inhibitors further indicates that the 
catalytic sites of γ-secretase are separated from the 
substrate-docking site(s) (50).  Our mutagenesis 
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study identified no restricted domain responsible 
for the cleavage specificity.  Rather, our results 
imply that the mutational effects are dependent 
not only on its position but also on substituting 
amino acids.  Additionally, the effects of PS1LA 
mutations were accomplished without obvious 
changes in the composition or subcellular 
localization of the PS1 complex.  These results 
are consistent with the hypothesis that the 
γ-secretase complex may have several 
conformational states linked to distinct γ-secretase 
activity and specificity.  Speculatively, as a 
result of subtle conformational change by PS1LA 
or FAD-linked missense mutations, substrates are 
presented in an aberrant position relative to the 
catalytic site, causing preferential cleavage at 
residue 42/43.  This effect must be subtle and 
highly specific, because different amino acid 
substitutions at the same residues in PS1 cause 
distinct modifications on γ-secretase activity.  
     DFK167 and sulindac sulfide are thought to 
shift the predominant cleavage site, probably 
through allosteric effects induced by direct PS 
binding (38, 47, 50, 51).  Several of our 
observations suggest that the effects of PS1 
mutations and the allosteric effects of γ-secretase 
inhibitors are likely to be tightly related, and we 
speculate that these effects might even be 
mediated by a shared mechanism.  First, our 
results and previously published data (32-34) 
show that PS1 mutations clearly modify the 
response of γ-secretase to these inhibitors.  
Second, γ-42/43 cleavage enhanced by PS1LA 
mutations was not further augmented by DFK167 
treatment, suggesting that the effect of PS1 
mutations and DFK167 treatment on Aβ42/43 
upregulation share the common plateau level.  
Third, similar to the case of γ-secretase inhibitor 
effect, the effect of PS1 mutations on γ-42/43 
cleavage is distinct from that on γ-40 and 
ε-cleavage.  Fourth, the paradoxical effect of 
γ-secretase inhibitors can recover the activities 
that are inactivated by PS1 mutations.  For 
examples, DFK167 activates endoproteolysis of 
PS1LA holoproteins and activates γ-42/43 cleavage 
by WT-PS1, whereas sulindac sulfide activates 
the γ-40 cleavage which is suppressed by PS1LA 
mutations.  
     Taking these observations together, we 
speculate that various missense mutations of PS1 
and the allosteric effects of γ-secretase inhibitors 
could modulate the cleavage specificity of 
γ-secretase by the same mechanism, namely a 
conformational change in the complex.  Very 
recent pharmacological or indirect morphological 
assessment also indicates that NSAIDs alter PS1 
conformation (51, 52).  Further, our results 
suggest a possible reciprocal relationship between 
γ-40 and γ-42/43 activities.  Taken together, 
these results also suggest that small molecules 
could be designed to induce alternate PS complex 
conformations that are more favorable to the 
generation of Aβ40 rather than pathogenic Aβ42/43.  
Such a strategy would obviate the complications 
of current γ-secretase inhibitor strategies that 
block all PS-dependent cleavage, including the 
cleavage of biologically important molecules like 
the Notch receptors. 
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FIGURE LEGENDS 
 
Fig. 1.  Endoproteolysis-impaired missense mutant PS1 proteins form stable, high molecular 
weight complexes.  A, Impaired endoproteolysis of mutant PS1 proteins.  The membrane fraction from 
PS-null MEFs transiently transfected with each PS1 mutant was immunoblotted with anti-PS1 antibody.  
WT-PS1 and the loss-of-function mutant, D385A-PS1, served as controls.  B, A scheme showing the 
location of mutated residues in PS1 mutants on the 8-TM model.  C, Glycerol velocity gradient fractions 
of CHAPSO lysates from PS1-transfected HEK293 cells were analyzed for PS1.  The positions of 
molecular weight markers are indicated at the top of the panel.  Results are representative of three 
independent experiments.  D, After treatment with 25 µg/ml cycloheximide for the indicated time, the 
lysate from HEK293 cells stably expressing each PS1 was detected using anti-PS1 antibody. 
 
Fig. 2.  PS-dependent protease activities in mutant PS1-expressing HEK293 cells.  A, ε-Cleavage 
in cells stably expressing mutant PS1 and APP-C99.  AICD fragments generated from 0.5% 
CHAPSO-extracted membrane fractions were evaluated by immunoblotting with an anti-APP antibody.  
WT-PS1 and the loss-of-function mutant, D385A-PS1, served as controls.  Results are representative of 
at least three independent experiments.  B, S3 cleavage of Notch in mutant PS1-expressing cells.  After 
transient transfection with NotchΔE-Myc, mutant PS1-expressing cells were metabolically pulse-labeled 
and chased for 1 h.  Immunoprecipitates with anti-Myc antibody were analyzed by polyacrylamide gel 
electrophoresis.  An autoradiograph of the dried gel is shown.  C, Aβ secretion from cells expressing 
WT or mutant PS1.  Aβ40 and Aβ42/43 levels in the conditioned media were quantified by ELISA.  Data 
represent the means ± s.d. (n=3).  *p < 0.001 by one-way ANOVA with Dunnett’s post-hoc test as 
compared with the values in WT PS1 cells.  
 
Fig. 3.  γ-Secretase activities of mutant PS1 on a PS-null background.  A, Aβ secretion from PS-null 
MEFs transfected with mutant PS1.  PS-null MEFs were retrovirally co-transfected with PS1 and APP, 
and secreted Aβ levels were measured by ELISA.  Data represent the means ± s.d. (n = 3).  Lower 
panels show the immunoblots for transfected PS1, APP, and secreted APP ectodomain (s-APP).  B, The 
profile of Aβ species secreted from PS-null MEFs transfected with WT, R278I- or L435H-PS1 was 
analyzed using IP/MS.  C, Secreted Aβ levels from PS-null MEFs co-transfected with human APP and 
indicated PS1 constructs were measured by ELISA.  The ratios of Aβ42/43 to total Aβ are shown.  Data 
represent the means ± s.d. (n = 3).  
 
Fig. 4.  Subcellular localization of PS1 and cleavage specificity of γ-secretase.  A, PS-null MEFs 
retrovirally transfected with WT or R278I-PS1 were investigated by immunocytochemistry.  
Immunoreactivities for PS1 CTF and the Golgi marker protein, p115, are shown in red and green, 
respectively.  Merged images show localization of PS1 in the Golgi apparatus as yellow fluorescence.  
B and C, HEK293 cells stably transfected with WT or R278I-PS1 were fractionated by sucrose density 
centrifugation.  The fractionated proteins were analyzed by immunoblottting with an anti-PS1 (B) or 
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anti-Nct (C) antibody.  D, The Aβ generated in cell-free systems in CHAPSO lysates of membrane 
fractions from HEK293 cells overexpressing each PS1 was assessed by ELISA.  The ratios of Aβ42/43 to 
total Aβ are shown.  Data represent the means ± s.d. (n = 3).  
 
Fig. 5.  γ-Secretase activity of PS1 with mutations at residue 278 or 433.  A, PS1 mutants containing 
six different substitutions at R278 were transfected into PS-null MEFs.  An immunoblot for transfected 
PS1 is shown in the upper panel.  The graph shows Aβ levels in the conditioned media as estimated by 
ELISA.  Values represent the means ± s.d. (n = 3).  *p<0.001 by one-way ANOVA with Dunnett’s 
post-hoc test.  B, PS1 mutants containing eight different substitutions at P433 were transfected into 
PS-null MEFs.  Shown is an immunoblot for PS1 (upper panel) and Aβ levels in the conditioned media 
(graph).  Values represent the means ± s.d. (n = 3).  
 
Fig. 6.  Effect of DFK167 and sulindac sulfide on Aβ  secretion and PS1 endoproteolysis.  A and B, 
PS-null MEFs co-transfected with human APP and WT-, I143F-, or R278I-PS1 were treated for 12 h with 
the indicated concentrations of DFK167 or sulindac sulfide, and Aβ40 and Aβ42/43 in the medium were 
measured by ELISA.  Data represent the means ± s.d. (n = 3).  C, After DFK167 treatment of mutant 
PS1-expressing MEFs for 12 h, PS1 endoproteolysis was estimated by immunoblotting with an anti-PS1 
CTF antibody.  The results are representative of three independent experiments.  






